Data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies, that selectively kills cancer cells and is thousands-fold better tolerated by healthy cells than previous NAMPT inhibitors. First presentation showcasing Remedy Plan’s unique,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.